GC4419: Phase Ib/IIa data

An open-label, dose-escalation, U.S. Phase Ib/IIa trial in 34 evaluable patients with head and neck cancer showed

Read the full 170 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE